# A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome

> **NCT03189160** · PHASE2 · UNKNOWN · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Turner Syndrome

## Interventions

- **BIOLOGICAL:** PEG-rhGH low dose
- **BIOLOGICAL:** PEG-rhGH high dose
- **OTHER:** Non-treatment control group

## Key facts

- **NCT ID:** NCT03189160
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2018-03
- **Final completion:** —
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2017-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189160, "A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03189160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*